Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Official Title

Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Suspected or biopsy-proven renal cell carcinoma* Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, nivolumab alone or in combination with an investigational agent* Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
  1. * Serum creatinine greater than or equal to 1.7 mg/dL* Severe allergy to contrast agent* Any contraindication for undergoing a CT scan* Pregnancy or unwillingness to use preventative measures if a woman of child-bearing potential


Aya Kamaya, MD
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
Alice C. Fan
Alice C. Fan
Medical oncologist, Genitourinary specialist
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Benjamin I. Chung
Benjamin I. Chung
Urologic oncologist, Urologic specialist, Urologist, Genitourinary specialist, Urologic surgeon
Associate Professor of Urology
Dean W. Felsher
James D. Brooks
James D. Brooks
Surgical oncologist, Urologic surgeon
Keith and Jan Hurlbut Professor
Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology
Chiara Sabatti
Dominik Fleischmann
Dominik Fleischmann
Radiologist, Cardiologist
Professor of Radiology (Cardiovascular Imaging)

Contact us to find out if this trial is right for you.


Yoriko Imae